Clinical trials: Glioma Glioblastoma Multiforme
Glioblastoma Multiforme, Glioblastoma, Adult
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
- Trial name
- IMA950-106 (NCT03665545)
- Testing
- IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Glioblastoma
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at…
- Trial name
- GLIOSTELLA (NCT06336291)
- Testing
- L19TNF, Lomustine
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Philogen S.p.A.
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
- Trial name
- NCT03403803
- Testing
- Optune
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Glioblastoma
Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity
This is an observational study on GBM surgical samples to investigate if increasing doses of radiation therapy could improve the radiation response; and in particular the investigators will assess if there is a correlation…
- Trial name
- GEHIRN (NCT05556382)
- Testing
- radiation of brain tissue specimen and dna damage analysis
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly…
- Trial name
- NCT05187624
- Testing
- RO7428731
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
High Grade Glioma, Glioblastoma
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been…
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT07859059
- Testing
- Dexbrompheniramine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Nebraska
Glioblastoma Multiforme
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how…
- Trial name
- NCT01209442
- Testing
- Bevacizumab, Temozolomide, RT (Radiation Therapy)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Glioblastoma Multiform (Grade IV Astrocytoma)
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective…
- Trial name
- DESSTINI_A (NCT01833273)
- Testing
- PolyMVA
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stony Brook University
Glioblastoma
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
- Trial name
- NCT00961090
- Testing
- Aminolevulinic Acid
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Matthew R Quigley
High Grade Gliomas, Brain Tumors
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Background: Radiation therapy with temozolomide (an anti-cancer drug) is standard therapy for treating brain tumors called glioblastomas.
- Trial name
- NCT00302159
- Testing
- adjuvant therapy, Temozolomide, Valproic Acid
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Astrocytoma, Grade IV
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Glioblastomas (GBM) are the most common type of primary brain tumors with an annual incidence of approximately 500 patients in the Netherlands.
- Trial name
- NCT02432417
- Testing
- Chloroquine
- Sponsor
- Maastricht Radiation Oncology
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Glycolytic Index
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors.
- Conditions
- Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
- Trial name
- NCT06059690
- Testing
- pH Measurement of in vivo tissue
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, High-Grade Gliomas
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Gliomas, Grade III Astrocytoma, Grade III Glioma
- Trial name
- NCT06975332
- Testing
- Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Glioblastoma
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
The primary protocol objective is to assess the impact of substituting pulsed reduced dose radiotherapy (pRDR) for standard radiation therapy in the upfront treatment of glioblastoma (GBM) on disease progression.
- Trial name
- NCT04747145
- Testing
- Radiation, Concurrent Chemotherapy (Temozolomide), Adjuvant Chemotherapy (Temozolomide)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical College of Wisconsin
Recurrent Glioblastoma
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.
- Trial name
- NCT04051606
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center